Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
New Launch of TAVALISSE for Chronic Idiopathic Thrombocytopenic Purpura in South Korea
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : JW Pharmaceutical Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Marketing Authorization for the Spleen Tyrosine Kinase Inhibitor TAVALISSE in South Korea
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : JW Pharmaceutical Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Tai Tien Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mitsubishi Tanabe Pharma Signs Fostamatinib Sub-Licensing Agreement with Kissei
Details : Under the licensing agreement, Tai Tien will gain the rights to develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) in Taiwan.
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Tai Tien Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Marketing Authorization in Japan for TAVALISSE, a Spleen Tyrosine Kinase Inhibitor
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2022
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Submission of NDA for Fostamatinib, an oral spleen tyrosine kinase inhibitor, in Japan
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Results from Japan Phase III of Fostamatinib for Immune Thrombocytopenic Purpura
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inmagene Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor Fostamatinib with Inmagene
Details : Inmagene will be responsible for the development and commercialization rights in China for Tavalisse (fostamatinib), a spleen tyrosine kinase inhibitor for treating immune thrombocytopenia.
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 05, 2021
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inmagene Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : JW Pharmaceutical Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sub-licensing Agreement for Fostamatinib with JW Pharmaceutical Corporation
Details : JW Pharma will be responsible for the development and commercialization rights in Korea for Tavalisse (fostamatinib), a spleen tyrosine kinase inhibitor for treating immune thrombocytopenia.
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : JW Pharmaceutical Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Participation in Global Phase III Clinical Trial For CG0070, a Drug for Bladder Cancer
Details : CG0070, a oncolytic immunotherapy in which adenovirus is genetically modified to enhance bladder tumor cells selectivity and anticancer activity, and is injected into the bladder using a urinary tract catheter.
Product Name : CG0070
Product Type : Microorganism
Upfront Cash : Inapplicable
March 24, 2021
Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : EA Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.
Product Name : AJM300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2021
Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : EA Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable